FINWIRES · TerminalLIVE
FINWIRES

Warby Parker Faces 'Challenging' Q1 on Weather, Consumer Pressure, UBS Says

By

-- Warby Parker (WRBY) is expected to post a "challenging" Q1, UBS Securities said, adding that results will likely be impacted by "severe winter weather" and increasing pressure on the consumer from rising gasoline prices.

The brokerage said in a Monday research note that the retailer's "core cash paying customer may have faced added stress," pointing to higher fuel costs and broader macro uncertainty, with pressure especially affecting younger and lower-income consumers.

UBS noted that Q1 growth would represent the company's slowest pace on record, highlighting the extent of a slowdown. It added that recent commentary suggests Warby is "braced for more downside vs upside risk from the consumer."

The investment firm also flagged that margins may face pressure from tariffs, cost deleverage in COGS and SG&A, and other input costs, though some of that could be offset by price increases, mix shift toward higher-margin products and cost mitigation efforts.

However, the firm said the "smart glasses opportunity" remains the key near-term driver for the stock and highlighted it as a potential catalyst.

UBS has a neutral rating on the company's stock, with a $25 price target.

Price: $21.65, Change: $-0.34, Percent Change: -1.55%

Related Articles

Mining & Metals

Earnings Flash (KBL.TO) K-Bro Linen Reports Q1 Revenue $139.1M, Up 52.9% YoY

$KBL.TO
Equities

Occidental Petroleum Q1 Adjusted Earnings Rise, Revenue Falls

Occidental Petroleum (OXY) reported Q1 adjusted earnings late Tuesday of $1.06 per diluted share, up from $0.87 a year earlier.Analysts polled by FactSet expected $0.60.Revenue for the three months ended March 31 was $5.23 billion, down from $5.70 billion a year earlier.Analysts surveyed by FactSet expected $5.44 billion.

$OXY
Mining & Metals

Curaleaf Swings to Q1 Profit As Revenues Beat Expectations

Curaleaf (CURA.TO) reported a swing to a surprise first-quarter profit, boosted by better than expected revenues.The company reported net income from continuing operations of US$70.1 million, or US$0.09 per share, compared with a loss of US$50.1 million, or a loss of US$0.09 per share. Analysts polled by FactSet had forecast a loss of US$0.08 per share.Revenue climbed 6% over the same period, to US$324 million, beating the US$317 million forecast."The macro headwinds that constrained growth over the past three years are now beginning to turn into meaningful tailwinds. Moreover, the historic rescheduling of medical cannabis provides a shift in the trajectory of our business and the industry overall, for which we are well-positioned," said chief executive Boris Jordan. "The investments we've made in the core pillars of our "Built for Growth" strategy are translating directly into tangible performance," he added.Curaleaf shares closed up $0.28, to $4.73 on Tuesday on the Toronto Stock Exchange.

$CURA.TO$HMMJ.TO